ArticleJACC. Case reports2026
Implantable Cardioverter-Defibrillators in Pregnant Individuals: Perinatal Management and Outcomes.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence-based guidance for pregnancy management in patients with implantable cardioverter-defibrillators (ICDs) includes careful multidisciplinary antepartum and delivery planning.
methodsCase series describing outcomes of 23 pregnancies among 9 patients with arrhythmias and ICDs.
resultsAmong the 9 patients all 23 pregnancies were carried to term, 13 of which were managed by our cardio-obstetrics program from March 2010 to October 2025. Median delivery gestational age was 39.3 weeks. Primary cesarean delivery rate was 55.5%, with cesareans performed for obstetric indications. Three pregnancies experienced cardiac complications: antepartum ventricular tachycardia, postpartum atrial fibrillation, and postpartum heart failure. No patients experienced inappropriate firings or device complications.
conclusionsMost patients in our case series experienced excellent perinatal and cardiac outcomes, with a maternal cardiac event rate of 13.0%. Our case series highlights the crucial role of coordinated multidisciplinary care, including antiarrhythmic therapy, fetal surveillance, labor and delivery planning, and close follow-up during the postpartum period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.